Literature DB >> 3305443

Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL).

P Littman, P Coccia, W A Bleyer, J Lukens, S Siegel, D Miller, H Sather, D Hammond.   

Abstract

Five hundred four children with low risk acute lymphocytic leukemia (previously untreated, age 3 to 6 years with white blood counts less than 10,000/mm3 at diagnosis) were randomized into two different central nervous system prophylaxis regimens. One regimen (250 patients) consisted of cranial radiation and intrathecal methotrexate (IT MTX). The second regimen (254 patients) consisted of IT MTX only. Median follow-up time for surviving patients is currently 54 months from randomization. Life table analysis of central nervous relapse, marrow relapse, disease-free survival, and survival shows very similar outcome for both treatment groups. The results indicate that maintenance IT MTX as described in this report can be substituted for cranial radiation in children with low risk ALL.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3305443     DOI: 10.1016/0360-3016(87)90308-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

Review 1.  Intrathecal chemotherapy with antineoplastic agents in children.

Authors:  A Ruggiero; V Conter; M Milani; E Biagi; I Lazzareschi; P Sparano; R Riccardi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Recent advances in management of acute leukaemia.

Authors:  J M Chessells
Journal:  Arch Dis Child       Date:  2000-06       Impact factor: 3.791

Review 3.  Central nervous system-directed therapy in the treatment of childhood acute lymphoblastic leukemia and studies of neurobehavioral outcome: Children's Cancer Group trials.

Authors:  Thomas A Kaleita
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

4.  Milestones in the curability of pediatric cancers.

Authors:  Melissa M Hudson; Michael P Link; Joseph V Simone
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

Review 5.  Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.

Authors:  Melissa M Hudson; Joseph P Neglia; William G Woods; John T Sandlund; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Daniel M Green
Journal:  Pediatr Blood Cancer       Date:  2011-10-28       Impact factor: 3.167

6.  Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation.

Authors:  J M Chessells; T C Cox; B Kendall; N P Cavanagh; L Jannoun; S Richards
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

Review 7.  An odyssey in search of a cure: the evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom.

Authors:  V Saha; T Eden
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 8.  A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.

Authors:  Inna V Fedorenko; Brittany Evernden; Rajappa S Kenchappa; Solmaz Sahebjam; Elena Ryzhova; John Puskas; Linda McIntosh; Gisela Caceres; Anthony Magliocco; Arnold Etame; J William Harbour; Keiran S M Smalley; Peter A Forsyth
Journal:  Melanoma Res       Date:  2016-10       Impact factor: 3.599

Review 9.  Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.

Authors:  Sue Richards; Ching-Hon Pui; Paul Gayon
Journal:  Pediatr Blood Cancer       Date:  2012-06-12       Impact factor: 3.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.